Cochrane · systematic review · CD010347
Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
Chauhan, BF, Jeyaraman, MM, Singh Mann, A, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
18
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 38.9%Moderate 8 · 44.4%High 3 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table 1
Population: adults and adolescents with persistent asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks | RR 0.5 [0.29, 0.86] | 4 studies · 815 participants | Moderate Downgraded: risk of bias |
Change from baseline in morning PEFR (L/min) Duration of trials: 6 to 16 weeks | no estimate extracted | 4 studies · 1489 participants | High |
Change from baseline FEV1 (L) Duration of trials: 6 to 16 weeks | no estimate extracted | 3 studies · 760 participants | High |
Change from baseline in mean asthma symptom score (daytime) Greater the reduction, better the outcome Duration of trials: 6 to 16 weeks | no estimate extracted | 3 studies · 1386 participants | High |
Overall adverse effects Duration of trials: 6 to 16 weeks | RR 1.06 [0.92, 1.22] | 3 studies · 1024 participants | Moderate Downgraded: risk of bias, imprecision |
Death Duration of trials: 6 to 16 weeks | RR 0.35 [0.01, 8.49] | 2 studies · 761 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table 2
Population: adults and adolescents with persistent asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patients with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 13 weeks | RR 0.9 [0.58, 1.39] | 4 studies · 1779 participants | Moderate Downgraded: imprecision |
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks | no estimate extracted | 5 studies · 952 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Change from baseline FEV1 (L) Duration of trials: 8 to 13 weeks | no estimate extracted | 4 studies · 958 participants | Low Downgraded: imprecision |
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks | no estimate extracted | 3 studies · 1539 participants | Moderate Downgraded: imprecision |
Overall adverse effects Duration of trials: 8 to 16 weeks | RR 0.96 [0.89, 1.03] | 6 studies · 1899 participants | Low Downgraded: imprecision |
Death Duration of trials: 12 to 13 weeks | no estimate extracted | 3 studies · 834 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings table 3
Population: adults and adolescents with persistent asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
% change from baseline ICS dose Duration of trials: 12 to 24 weeks More reduction is better | no estimate extracted | 4 studies · 930 participants | Moderate Downgraded: imprecision |
Participants with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 24 weeks | RR 0.46 [0.2, 1.04] | 5 studies · 542 participants | Low Downgraded: imprecision |
Change from baseline in morning PEFR (L/min) Duration of trials: 12 to 24 weeks | no estimate extracted | 2 studies · 218 participants | Moderate Downgraded: imprecision |
Overall adverse effects Duration of trials: 8 to 24 weeks | RR 0.95 [0.83, 1.08] | 6 studies · 1100 participants | Moderate Downgraded: imprecision |
Serious adverse events Duration of trials: 12 to 20 weeks | RR 2.44 [1.52, 3.92] | 2 studies · 621 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Death Duration of trials: 8 to 24 weeks | RR 3.1 [0.13, 75.1] | 6 studies · 1100 participants | Low Downgraded: risk of bias, imprecision, indirectness |